Gujarat kidney and super speciality Limited has completed payment of regulatory fines totaling ₹6,60,800 to both major Indian stock exchanges for failing to comply with mandatory financial reporting requirements. The healthcare company paid the penalties on March 20, 2026, following penalty notices received from NSE and BSE on March 17, 2026.

Penalty Payment Details

The company has settled the fines imposed by both stock exchanges for violating Regulation 33 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015. The penalties were paid via RTGS at 3:15 PM on March 20, 2026.

Regulatory Violation and Compliance

The penalty stems from the company's failure to submit financial results for the quarter ended September 30, 2025 within the prescribed timeline under Regulation 33 of LODR 2015. Both exchanges imposed identical fines for non-submission of quarterly financial results within the stipulated period.

The company has now fulfilled its payment obligations within the timelines prescribed by both stock exchanges, ensuring compliance with the penalty orders.

Company's Official Communication

Company Secretary and Compliance Officer Niki Tiwari formally communicated the penalty payment to both stock exchanges on March 21, 2026, under Regulation 30 of the listing regulations. The communication was digitally signed and submitted with proper documentation as required under SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024.

Financial Impact Assessment

According to the company's official disclosure, since the total penalty amount of ₹6,60,800 has been paid in full, no further payments are required. The company has stated that there is no additional financial impact expected from this regulatory action, and the penalty settlement closes the matter with both exchanges.

The healthcare company continues its operations without any material impact on its financial, operational, or other business activities following the penalty payment completion.

Gujarat Kidney And Superspeciality Limited conducted a board meeting on March 19, 2026, addressing several important corporate governance matters and making key appointments for the Financial Year 2025-26. The meeting, held at the company's registered office from 05:15 P.M. to 06:15 P.M., resulted in significant decisions regarding auditor appointments, postal ballot approval, and ratification of financial results.

Key Board Decisions

The board approved multiple critical appointments and corporate actions during the meeting:

Auditor Appointments

Secretarial Auditor Profile: Mr. Dharmendra Bhaliya brings substantial expertise as an Associate member of the Institute of Company Secretaries of India (ICSI). He holds a master's degree in commerce and is a law graduate, currently working as a Practicing Company Secretary. His experience spans approximately 5 years in corporate laws including the Companies Act 2013, SEBI Act and regulations, and the Foreign Exchange Management Act 1999 (FEMA). He maintains a valid peer review certificate from ICSI.

Internal Auditor Profile: Mr. Siddharth Atulbhai Shah serves as an Associate member of the Institute of Chartered Accountants of India (ICAI) with around 7 years of experience in Assurance, Internal Audit, IFC Forensic & Fraud Risk. His professional certifications include Forensic Accounting & Fraud Detection (ICAI), Alternative Dispute Resolution (ADR) covering Arbitration, Mediation & Conciliation, and Concurrent Bank Audit Certification (ICAI).

Q2 FY25 Financial Performance

The company's Q2 FY25 financial results, which were ratified during this meeting, demonstrate solid operational performance across both standalone and consolidated metrics.

Standalone Results (Q2 FY25):

Consolidated Results (Q2 FY25):

Regulatory Compliance

The board addressed a compliance matter regarding the February 14, 2026 meeting, where financial results were discussed and approved but not formally recorded due to misunderstanding about SEBI (LODR) Regulations applicability following the company's listing on December 30, 2025. The board ratified these actions and resubmitted the financial results with corrections to typographical errors via letter dated March 13, 2026.

Corporate Structure

The consolidated results include performance from the company's subsidiaries and entities under control: Gujarat Surgical Hospital, Surya Hospital and ICU, and Raj Palmland Hospital Private Limited. This diversified healthcare portfolio contributed to the stronger consolidated revenue performance compared to standalone operations.

The company continues to focus on its primary business segment of healthcare services, with the board ensuring proper governance structures are in place through these auditor appointments and regulatory compliance measures.